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Abstract
Introduction
Pleomorphic adenoma (PA) is the most frequent salivary gland tumour of the parotid gland
and can recur following surgical excision. Recurrent pleomorphic adenoma (RPA) of the
parotid gland can be a challenge to the clinical team and has variable outcomes. The aim of
this work is to present the current thinking in the management of this disease. This may be
helpful to clinical teams and could improve the health-related quality of life of patients.
Materials and methods
A search of several online databases was devised using the following key terms: Pleomorphic
adenoma, recurrent pleomorphic adenoma, parotid gland tumours, parotid surgery,
radiotherapy and parotid pleomorphic adenoma, parotid surgery outcomes. Information was
collected relating to the topic of the paper, sample size, recurrence rate, facial nerve status,
types of surgery, adjuvant treatments relating to recurrence, clinical outcome.
Results
2301 papers were screened, of which 49 articles eligible; There is no consensus amongst the
clinical teams for the management of RPA of the parotid gland. There is a lack of randomised
studies and hence conclusions in most papers are coherent arguments.
Discussion
RPA of the parotid gland tends to occur after long intervals, with propensity towards
multifocal disease. The risk of recurrence depends on the initial surgical technique, is higher
3when the initial surgery was at young age, after enucleation and after initial positive margins.
Based on the published papers accepted management varies from observation of selected
cases to total parotidectomy with/without postoperative radiotherapy.
4Introduction
The management of recurrent pleomorphic adenoma (RPA) of the parotid gland presents a
challenge to clinicians. This is because surgery is difficult, it is often multinodular1 and can
be associated with facial nerve compromise. Following recurrence there is an increased risk
for further recurrences and a risk of malignant transformation that is recently reported as
3.3%3. The time interval from the initial treatment can be as long as 15 years1. The recurrence
rates reported in the literature are depended on the initial surgery type. When a superficial
parotidectomy has been performed, the recurrence rate may be below 3%4. Tumour factors
that may have an influence on recurrence include tumour size5 pathological subtype6, satellite
nodules2, incompleteness of encapsulation7. In contemporary surgical practice, PA
enucleation is not performed anymore; partial/total parotidectomy or extra-capsular
dissection are the operations of choice at initial presentation. When surgical factors are
examined in detail, tumour spillage and / or positive margins are associated with
recurrences2. When examining patient factors, some published papers indicated that the
younger patients at initial presentation are those that are associated with later recurrences.
However, this conclusion is not robust at present5. There is paucity of well-designed studies
that defines the role of radiotherapy in the management of RPA of the parotid.   Surgeons
have a reluctance to advocate the routine use of radiotherapy due to the risks associated with
radiation induced malignancies, especially in young patients8. The published experiences
have been derived from studies on the use of radiotherapy in patients with incomplete
margins after their first episode of surgery. Radiotherapy appeared to reduce recurrence with
incomplete excision8. Chen et al9 (2006) evaluated the role of radiation therapy in the
management of recurrent pleomorphic adenoma of the parotid gland. In that study, the 20-
year local control rate was 94%. One patient (1 patient out of 34) developed a second
malignancy at approximately 14 years after completion of therapy. The aims of this review
5include evaluation of current practice and evidence-based understanding of the management
of RPA of the parotid in order to provide guidance to clinical teams.
Material and Methods
A search strategy was devised using the following key terms: Pleomorphic adenoma,
recurrent pleomorphic adenoma, parotid gland tumours, parotid surgery, radiotherapy and
parotid pleomorphic adenoma, parotid surgery outcomes.  The following databases were
examined: PubMed, Handle-on-qol, Medline, Ebase (Excerpta Medica), Science Citation
Index/Social Sciences Citation Index, Ovid Evidence-Based Medicine databases.
Only manuscripts written in English were included. All instruments included in PRISMA
guidance was considered in the search and presentation of the results10. A total of 2301
papers were identified. From an evaluation of the abstracts and available full text, 49 relevant
papers were closely examined (Figure 1). Information was collected relating to the topic of
the paper, sample size, recurrence rate, facial nerve status, types of surgery, adjuvant
treatments relating to recurrence, clinical outcome (current clinical status).
Results
The authors found 49 papers, which satisfied our inclusion criteria (Figure 1). Most studies
were retrospective case series. A detailed description has been presented in Table 11,2,9,11-56.
A superficial or a total parotidectomy are the operations of choice in RPA of the parotid
given the multicentricity of the lesions and the risk of further recurrences12,35. In selective
cases with small volume recurrent disease an extracapsular dissection may be employed. A
superficial or a total parotidectomy is the gold standard for the management of RPA but may
be inadequate to control disease. There is evidence from retrospective series that
postoperative radiation therapy improves local control15. Clear margins are essential but
6cannot guarantee a cure in RPA12,25. There is evidence now that PAs slowly gain malignant
characteristics after repeated recurrences21. Myxoid subtypes of PA tend to have incomplete
and thinner capsules and to recur more frequently. Larger PA tend not only to exhibit
incomplete capsules but in addition are associated with more numerous satellite nodules46.
Larger tumours seem, in most studies (Table 1), to be associated with more frequent
recurrences.  The use of Intraoperative Facial Nerve Monitoring during RPA parotidectomy
reduced the duration of surgery and the incidence of postoperative facial paralysis  (P < .01 and
P = .01, respectively) and reduced recovery time18.
A promising tool might be the intraoperative use of sodium fluorescein in case of recurrent
PA with a risk of damaging the facial nerve. With the help of this tool, which is integrated
into the microscope, nerve fibres can become visible for the surgeon, making dissection of
the nerve easier and allow for facial nerve preservation57,58. This technique is used by the
authors and allows for identification of nerve fibres if a standardized protocol is used57,58. The
correct timing of sodium fluorescein application makes nerve fibres visible, even in situations
of actual wound healing or patients who received radiotherapy 58,59. Although this technique
is new and needs further prospective evaluation, it might be suitable for patients with RPA
allowing facial nerve preservation.
Discussion
The management of RPA presents a challenge to the clinical team. Often there are multiple
local recurrences- that may not necessarily all be ‘visible’ during pre-operative imaging due
to their size- that may become apparent during the surgical intervention or during
histopathological examination. Despite the lack of randomized studies and the paucity of
prospective studies, the available data in this structured review seem to point toward a series
of coherent arguments.
7Controversies are evident from this work and mostly relate to the type of operation and the
use of post-operative radiotherapy. Often clinicians adopt a pragmatic view that takes into
account the location of the recurrent tumour, whether it is a multinodular or uninodular
recurrence, the size and the rate of growth as well as the patient’s co-morbidities. Selected
cases can be observed. Conservative surgical management can include partial superficial
parotidectomy or extracapsular dissection. In patients that are symptomatic but unfit for a
surgical intervention, radiotherapy could be suggested as an alternative for surgery. Total
parotidectomy, is appropriate in many patients, but may be inadequate to control recurrent
pleomorphic adenomas.  Adjuvant radiotherapy seem to significantly improved control in
multinodular recurrences 56.  Sometimes the clinical scenario may include elderly patients
with multifocal recurrences where the facial nerve is engulfed by scar and tumour. Limited
data55,60 suggested a role for radical parotidectomy with immediate nerve reconstruction.
Most clinicians though, will preserve the facial nerve whenever possible.  Lumpectomy is not
the operation of choice for the management of RPA and this is reflected in the literature1,2,3,
but there may be clinical situations that can be considered. This is little talked about but it
may be an entirely rational approach for the older, frail patient who may now have another
multi-focal recurrence, many years after primary treatment which spilled tumour, had
radiotherapy and then had recurrence with multiple nodules. The risk in this group is that
some of the nodules may undergo stochastic malignant change. In our experience, these were
usually the rapidly expanding nodules which could be safely excised as a lumpectomy,
clearing early carcinoma ex PSA and causing ‘minimal damage’ to patients with somewhat
limited life-expectancy. A radical parotidectomy with nerve reconstruction rather than a
‘lumpectomy’ may be inevitable in the latter scenario in a patient that is fit for an extensive
operation.
8It is evident from this work that we are lacking appropriately designed and powered
prospective multicentre randomised controlled studies that would better inform the clinical
teams and provide an improved patient outcome. This in part, is due to the nature of the
disease, its growth characteristics and often a long period between initial surgery and
recurrence. Despite the lack of level I evidence, using the current data a flow pathway may be
suggested (Figure 2). Another aspect of the management of RPA relates to the long term
clinical outcome. Although RPA metastases are rare13, we need to keep in mind that a high
percentage of RPA are incurable12. Patients need to be informed well about the potential need
of multiple operations over time, the adverse effect on the facial nerve and the rate of
malignant transformation3. In some circumstance (elderly patients with significant
comorbidities), best supportive care may be the only option.
A clear resection margin cannot guarantee a cure in RPA, and it seems that parotid
pleomorphic adenomas slowly gain malignant characteristics after repeated recurrences.
When marginal clearance is of clinical concern, options include further surgery or post-
operative radiotherapy. Patel et al (2014) demonstrated improved locoregional control for
patients with close or positive margins16. One reason for the reluctance –from the surgical
teams-to use radiation therapy is the fear of inducing a second malignant tumour in the
remaining gland or in other organs of the head and neck. However, the incidence and side
effects appeared to be low 16 with IMRT, this is something that need to be discussed in detail
especially in young patients. Recurrent operations are challenging and can result in poor
aesthetic or functional outcome in RPA, especially when the facial nerve is at increased risk
of damage due to previous extent of surgery or multifocal recurrences.  The data is limited
specifically to RPA, but the use of intraoperative facial nerve monitoring seem to reduce the
duration of surgery, enhance recovery and reducing the incidence of long term paralysis. This
appears to be a logical argument and a current practice in RPA surgery.
9Conclusions
The management of RPA of the parotid gland is challenging. There is a lack of randomised
and prospective studies but there is a large volume of retrospective studies that included
practises indicating good clinical outcomes. There is a need for some flexibility in the
management of this condition in order to accommodate current patient health, the natural
history of the disease and the effect of the treatment modalities in the patient’s quality of life.
Because of the complexity of the condition, there is need for tailored treatment. Surgeons
should be prepared to offer , in addition to a superficial / total parotidectomy , a radical
parotidectomy with immediate reconstruction or even a ‘lumpectomy’ on selective cases. The
relative low incidence of RPA and the requirement of a prolong follow-up, has adversely
affected progress.
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Case Report 1 Post-
operative
radiothera
py
Adjuvant
radiotherapy
can be given
in recurrent
multifocal
PA.
21
Liu H et al18
2014
58
Cohort study
58 RPA Total and
superficial
Parotidecto
my
The use of
IFNM during
total or wide
resection RPA
parotidectomy
reduced the
duration of
surgery and
the incidence
of
postoperative
facial
paralysis and
enhanced
recovery.
However,
there was
little impact
on facial
nerve
outcomes
when IFNM
was used
during
superficial
RPA
parotidectomy
.
Causevic VM
et al19
2014
60 patients
Retrospective
study
After
enucleation
(88.9%), then
after excision
(46.9%), and
the least after
superficial
(4%) and total
parotidectomy
(0%).
No
Total or
superficial
parotidectomy
were optimal
surgical
procedures
Strub GM et
al20
2012
1 patient
Case study
Total
parotidecto
my
Yes Transcranial
RPA, recurred
after 30 years
22
Becelli R et
al21
2012
1 patient
Case report
Conservati
ve
parotidecto
my
Yes
Park GC et
al2
110 patients
Retrospective
study
10 patients Superficial
parotidecto
my
Satellite
nodules and
tumor rupture
increase the
risk of
recurrence in
patients with
pleomorphic
adenomas
treated by
superficial
parotidectomy
Papadogeorg
akis N et al22
2012
1 Case report The
probability of
subsequent
recurrence
increases
with each
recurrent
episode, thus
making local
control
difficult and
damage to
the facial
nerve more
likely.
Soares AB et
al23
39 cases in total,
29 with RPA
This study
showed that
recurrences
were
multinodular
23
2011
Immunohistoche
mical study
Makeieff M
et al24
2010
62 consecutive
patients with RPA
New
recurrence
after surgery
is less
frequent if the
initial
treatment for
pleomorphic
adenoma is
total
parotidectom
y.
Surgery is
recommended
in
pleomorphic
adenoma
recurrence
because of the
high rate of
carcinoma ex
pleomorphic
adenoma
(16.1%)
Suh MW et
al25
270 patients
retrospective
study
A clear
resection
margin cannot
guarantee a
cure in RPA
Soares AB et
al26
2009
A total of 19 cases of
PA and 24 cases of
RPA
Immunohistochemica
l study
RPA presents
more
aggressive
clinical
behaviour
than PA
Bhutta MF et
al27
2010
1 case report Case of renal
metastasis of
a recurrent
pleomorphic
adenoma
24
Ghosh A et
al28
2008
1 case report PA of the
parotid gland
that
metastasized
to the
scapular
region
Redaelli de
Zinis LO29
2008
33 patients
Retrospective study
The estimated
tumour
recurrence
rates were
14.1+/-6.6% at
5 years,
31.4+/-9.4% at
10 years,
43.0+/-10.8%
at 15 years,
and 57.2+/-
14.8% at 20
years.
A total or
extended total
parotidectom
y was
performed in
16 cases
(48.5%), a
superficial
parotidectom
y in 10 cases
(30.3%), and
a local
excision in 7
cases
(21.2%).
RPAs are
prone to new
recurrences,
especially
when
multinodular
and treated
with a local
excision.
Surgical
treatment
should
include facial
nerve
resection in
selected cases
Wittekindt C
et al30
2007
134 RPA All RPA
patients
Extended
parotidectom
y
Extended
parotidectomy
seems to be
the best
approach for
the
reoperation to
reduce the
risk of
recurrence.
Steele NP et
al31
1 case report Case of
pleomorphic
adenoma of
the parotid
gland
25
2007 metastasizing
to a
mediastinal
lymph node
Chen AM et
al9
2006
34 patients treated
with post-operative
radiation
With a median
follow-up of
17.4 years
(range, 2.3-
28.9 years), 2
patients had
local
recurrences at
a median of
3.4 years after
completion of
radiation
Yes The use of
postoperative
radiation
therapy leads
to excellent
long-term
local control
for the
treatment of
recurrent
pleomorphic
adenoma with
acceptable
late toxicity.
Leonetti JP et
al32
2006
42 patients with RPA Total
parotidectom
y or subtotal
petrosectomy
with facial
nerve
resection
Two of 42
patients were
found to have
carcinoma ex-
pleomorphic
adenoma,
both of these
patients
underwent
prior
radiotherapy,
and both died
of metastatic
disease.
Maxwell EL
et al33
2004
35 RPA patients Locoregional
control rate of
77%.
Total
parotidectom
y
No Local
excision of
recurrent
disease is
sufficient in
controlling
further
recurrence.
Zbären P et
al34
33 patients with RPA Multifocal
recurrence and
carcinoma in
pleomorphic
adenoma were
observed in
73% and 9%
Enucleation
and
superficial
parotidectom
y
To evaluate
the re-
recurrence
rate, a follow-
up of at least
10 years is
necessary.
26
2005 of patients,
respectively.
Stennert E et
al35
2004
31 patients with RPA
prospective study
Most
recurrences
were
multinodular
Total
parotidectom
y
The myxoid
subtype was
predominant.
Koral K et
al36
2003
15 patients
retrospective study
The lesions
were multiple
in 73.3% of
patients
Glas AS37
2002
52 patients with RPA Progesterone
receptor
seems to be a
prognostic
factor in RPA
7 patients
retrospective study
Total
parotidectom
y with facial
nerve
preservation
Tumour
control rates
and facial
nerve
preservation
are enhanced
with formal
parotidectomy
27
Becelli R et
al38
2001
RowleyH et
al39
2000
12 patients with RPA
retrospective study
Superficial
parotidectom
y
Three
patients
required
adjuvant
radiotherapy.
Type of
recurrence
was
uninodular or
multinodular
Carew JF et
al40
1999
31 patients
retrospective study
More than
half of these
patients
underwent
total
parotidectom
y.
Better local
control was
seen in 11
patients who
received
postoperativ
e irradiation
(100% at 10
years) than
in 20
patients who
did not (71%
at 10 years;
P < 0.28)
Postoperative
radiation
therapy may
improve
control in
patients at
high risk for
another
recurrence.
Yasumoto M
et al41
1999
15 patients with RPA
retrospective study
Most
recurrent
pleomorphic
adenomas
were well
delineated
with smooth
margins, like
most primary
tumours.
Patel N et al42
1998
24 RPA patients
retrospective study
Recurrence
rates are
between 0-4%
Yes Radiotherapy
is
controversial,
it should be
considered if
there has been
tumour
28
spillage
following re-
operation.
Yugueros P
et al43
1998
39 patients with RPA
retrospective study
Yes When
previous
parotidectomy
has been
performed,
simple
excision with
a margin of
surrounding
tissue would
seem
appropriate.
Laskawi R et
al44
1998
94 RPA patients
retrospective study
Adequate
initial
operation to
avoid
recurrences of
pleomorphic
adenomas in
the parotid
gland.
Leverstein H
et al45
1997
40 patients with RPA. 16 received
postoperativ
e
radiotherapy
Recurrent
disease tends
to be
multifocal in
origin,
prolonged
routine
follow-up is
required.
Renehan A et
al46
1996
114 RPA patients
retrospective study
Yes Multinodular
tumours have
a high risk of
relapse-
advised
radiotherapy
29
Phillips PP et
al47
1995
126 patients with
RPA retrospective
study.
Recurrence
was 32.5%
These results
suggest low
morbidity and
good success
in tumour
eradication
with an
aggressive
surgical
approach.
Natvig K et
al48
1994
346 patients Six (2.5%)
patients had a
recurrence 7 to
18 years
postoperativel
y
No We also
question the
justification
and benefit of
postoperative
radiotherapy
for patients
with this
benign
disease.
Jackson SR et
al49
1993
209 patients
retrospective study
38 RPA Total /
Superficial
parotidectom
y
Buchholz
TA50
6 RPA
retrospective study
Yes Neutron
radiation also
carries a low
risk of facial
nerve
30
1992
damage, a
consideration
that may
argue for
limiting the
extent of
surgical
resection of
recurrent
disease.
Dawson
AK51
1989
29 patients were
treated by excision
and post-operative
irradiation following
RPA
Retrospective study
Eighteen of 20
(90%) patients
with a first
recurrence
were
controlled
comparing
favourably
with series
employing
surgery only.
Yes Radiation
therapy has a
role to play as
a surgical
adjuvant in
the
management
of these
tumors
Fleming
WB52
1987
19 RPA patients No
Radiotherapy
does not seem
to be an
appropriate
alternative to
repeated
surgical
excision.
Niparko JK et
al53
1986
48 RPA patients Malignant
conversion
developed in
three (6%) of
48 cases
Formal partial
or total
parotidectom
y
En bloc total
parotidectomy
offers
effective,
though not
absolute,
control of
extensive
recurrence.
31
Maran AG et
al54
1984
19 RPA retrospective
study
No
The suggested
treatment of
recurrence is
total
parotidectomy
with
preservation
of the facial
nerve.
Stanley RE et
al55
1984
19 RPA retrospective
study Eighteen out
of the 19
patients did
not have
further
recurrences
after revision
parotidectomy
.
Conley J et
al56
1979
Review The recurrence
rate for benign
mixed tumour
in the parotid
gland is
variously
reported in the
ranges of 0.5%
to 10%
